West Ebitda vs Cost Of Revenue Analysis

WST Stock

USD 360.43 7.75 2.10%

West Pharmaceutical financial indicator trend analysis is more than just analyzing West Pharmaceutical current accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether West Pharmaceutical is a good investment. Please check the relationship between West Pharmaceutical Ebitda and its Cost Of Revenue accounts. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in West Pharmaceutical Services. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.

Ebitda vs Cost Of Revenue

Ebitda vs Cost Of Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of West Pharmaceutical Ebitda account and Cost Of Revenue. At this time, the significance of the direction appears to have almost identical trend.

The correlation between West Pharmaceutical's Ebitda and Cost Of Revenue is 0.94. Overlapping area represents the amount of variation of Ebitda that can explain the historical movement of Cost Of Revenue in the same time period over historical financial statements of West Pharmaceutical Services, assuming nothing else is changed. The correlation between historical values of West Pharmaceutical's Ebitda and Cost Of Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ebitda of West Pharmaceutical Services are associated (or correlated) with its Cost Of Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cost Of Revenue has no effect on the direction of Ebitda i.e., West Pharmaceutical's Ebitda and Cost Of Revenue go up and down completely randomly.

Correlation Coefficient

0.94

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Ebitda

Cost Of Revenue

Cost of Revenue is found on West Pharmaceutical income statement and represents the costs associated with goods and services West Pharmaceutical provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Most indicators from West Pharmaceutical's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into West Pharmaceutical current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in West Pharmaceutical Services. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.

At this time, West Pharmaceutical's Sales General And Administrative To Revenue is comparatively stable compared to the past year. Enterprise Value Over EBITDA is likely to gain to 30.72 in 2024, whereas Enterprise Value is likely to drop slightly above 252.4 M in 2024.

	2021	2022	2023	2024 (projected)
Total Revenue	2.8B	2.9B	2.9B	3.1B
Depreciation And Amortization	126.1M	120.6M	137.3M	144.2M

Total Revenue Depreciation And Amortization

West Pharmaceutical fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Accounts Payable	Property Plant And Equipment Gross	Common Stock Total Equity	Common Stock
Total Assets		0.33	0.96	0.98	0.98	0.98	-0.87	0.97	0.97	0.98	0.51	0.97	0.98	0.67	0.12	0.99	0.91	-0.7	0.76	0.99	0.58	-0.35	0.98	0.94	0.54	0.54
Short Long Term Debt Total	0.33		0.41	0.31	0.17	0.29	0.09	0.13	0.2	0.4	0.23	0.21	0.23	0.49	0.93	0.27	0.24	0.03	0.65	0.23	-0.02	0.73	0.3	0.14	0.3	0.29
Other Current Liab	0.96	0.41		0.97	0.93	0.92	-0.83	0.9	0.94	0.94	0.62	0.94	0.96	0.69	0.21	0.96	0.86	-0.59	0.81	0.96	0.47	-0.25	0.98	0.87	0.53	0.53
Total Current Liabilities	0.98	0.31	0.97		0.96	0.96	-0.86	0.96	0.95	0.96	0.52	0.95	0.96	0.65	0.08	0.98	0.92	-0.72	0.76	0.97	0.64	-0.33	0.98	0.93	0.49	0.5
Total Stockholder Equity	0.98	0.17	0.93	0.96		0.97	-0.93	0.99	0.98	0.96	0.46	0.98	0.99	0.63	-0.04	0.99	0.91	-0.72	0.66	0.99	0.58	-0.5	0.97	0.96	0.54	0.55
Property Plant And Equipment Net	0.98	0.29	0.92	0.96	0.97		-0.83	0.97	0.93	0.99	0.35	0.93	0.96	0.71	0.1	0.98	0.91	-0.71	0.68	0.96	0.65	-0.35	0.96	0.93	0.58	0.58
Net Debt	-0.87	0.09	-0.83	-0.86	-0.93	-0.83		-0.93	-0.95	-0.79	-0.5	-0.95	-0.92	-0.44	0.32	-0.9	-0.79	0.69	-0.5	-0.93	-0.46	0.71	-0.87	-0.89	-0.47	-0.48
Retained Earnings	0.97	0.13	0.9	0.96	0.99	0.97	-0.93		0.97	0.94	0.41	0.97	0.97	0.56	-0.09	0.98	0.93	-0.81	0.66	0.98	0.64	-0.51	0.94	0.98	0.46	0.47
Cash	0.97	0.2	0.94	0.95	0.98	0.93	-0.95	0.97		0.92	0.55	1.0	0.98	0.57	-0.03	0.98	0.88	-0.71	0.71	0.99	0.5	-0.48	0.96	0.94	0.51	0.52
Non Current Assets Total	0.98	0.4	0.94	0.96	0.96	0.99	-0.79	0.94	0.92		0.4	0.92	0.95	0.76	0.22	0.97	0.9	-0.64	0.74	0.95	0.59	-0.25	0.97	0.9	0.59	0.6
Non Currrent Assets Other	0.51	0.23	0.62	0.52	0.46	0.35	-0.5	0.41	0.55	0.4		0.55	0.54	0.29	0.14	0.5	0.45	-0.14	0.55	0.54	0.03	-0.11	0.53	0.45	0.12	0.12
Cash And Short Term Investments	0.97	0.21	0.94	0.95	0.98	0.93	-0.95	0.97	1.0	0.92	0.55		0.98	0.56	-0.02	0.98	0.88	-0.71	0.71	0.99	0.49	-0.47	0.96	0.94	0.51	0.51
Net Receivables	0.98	0.23	0.96	0.96	0.99	0.96	-0.92	0.97	0.98	0.95	0.54	0.98		0.67	0.03	0.99	0.9	-0.66	0.71	0.99	0.52	-0.45	0.98	0.93	0.55	0.56
Common Stock Shares Outstanding	0.67	0.49	0.69	0.65	0.63	0.71	-0.44	0.56	0.57	0.76	0.29	0.56	0.67		0.43	0.67	0.57	-0.06	0.42	0.62	0.28	0.02	0.72	0.48	0.75	0.76
Non Current Liabilities Total	0.12	0.93	0.21	0.08	-0.04	0.1	0.32	-0.09	-0.03	0.22	0.14	-0.02	0.03	0.43		0.07	0.03	0.26	0.48	0.02	-0.21	0.84	0.1	-0.09	0.17	0.16
Inventory	0.99	0.27	0.96	0.98	0.99	0.98	-0.9	0.98	0.98	0.97	0.5	0.98	0.99	0.67	0.07		0.91	-0.7	0.72	0.99	0.57	-0.4	0.98	0.95	0.55	0.55
Other Current Assets	0.91	0.24	0.86	0.92	0.91	0.91	-0.79	0.93	0.88	0.9	0.45	0.88	0.9	0.57	0.03	0.91		-0.81	0.73	0.91	0.67	-0.34	0.87	0.95	0.32	0.33
Other Stockholder Equity	-0.7	0.03	-0.59	-0.72	-0.72	-0.71	0.69	-0.81	-0.71	-0.64	-0.14	-0.71	-0.66	-0.06	0.26	-0.7	-0.81		-0.57	-0.71	-0.73	0.45	-0.62	-0.85	0.02	0.01
Total Liab	0.76	0.65	0.81	0.76	0.66	0.68	-0.5	0.66	0.71	0.74	0.55	0.71	0.71	0.42	0.48	0.72	0.73	-0.57		0.73	0.31	0.13	0.72	0.67	0.15	0.16
Total Current Assets	0.99	0.23	0.96	0.97	0.99	0.96	-0.93	0.98	0.99	0.95	0.54	0.99	0.99	0.62	0.02	0.99	0.91	-0.71	0.73		0.53	-0.44	0.97	0.95	0.52	0.53
Short Term Debt	0.58	-0.02	0.47	0.64	0.58	0.65	-0.46	0.64	0.5	0.59	0.03	0.49	0.52	0.28	-0.21	0.57	0.67	-0.73	0.31	0.53		-0.29	0.55	0.68	0.12	0.13
Intangible Assets	-0.35	0.73	-0.25	-0.33	-0.5	-0.35	0.71	-0.51	-0.48	-0.25	-0.11	-0.47	-0.45	0.02	0.84	-0.4	-0.34	0.45	0.13	-0.44	-0.29		-0.37	-0.49	-0.16	-0.16
Accounts Payable	0.98	0.3	0.98	0.98	0.97	0.96	-0.87	0.94	0.96	0.97	0.53	0.96	0.98	0.72	0.1	0.98	0.87	-0.62	0.72	0.97	0.55	-0.37		0.9	0.59	0.6
Property Plant And Equipment Gross	0.94	0.14	0.87	0.93	0.96	0.93	-0.89	0.98	0.94	0.9	0.45	0.94	0.93	0.48	-0.09	0.95	0.95	-0.85	0.67	0.95	0.68	-0.49	0.9		0.37	0.38
Common Stock Total Equity	0.54	0.3	0.53	0.49	0.54	0.58	-0.47	0.46	0.51	0.59	0.12	0.51	0.55	0.75	0.17	0.55	0.32	0.02	0.15	0.52	0.12	-0.16	0.59	0.37		1.0
Common Stock	0.54	0.29	0.53	0.5	0.55	0.58	-0.48	0.47	0.52	0.6	0.12	0.51	0.56	0.76	0.16	0.55	0.33	0.01	0.16	0.53	0.13	-0.16	0.6	0.38	1.0

Click cells to compare fundamentals

West Pharmaceutical Account Relationship Matchups

West Pharmaceutical fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	2.3B	2.8B	3.3B	3.6B	3.8B	4.0B
Short Long Term Debt Total	329.3M	325.7M	325.3M	317.9M	309M	227.6M
Other Current Liab	145.4M	226.9M	259.7M	228.1M	236M	247.8M
Total Current Liabilities	341.6M	503.4M	594.1M	519M	671.8M	705.4M
Total Stockholder Equity	1.6B	1.9B	2.3B	2.7B	2.9B	3.0B
Property Plant And Equipment Net	909.4M	1.0B	1.1B	1.3B	1.5B	1.6B
Net Debt	(109.8M)	(289.8M)	(437.3M)	(576.4M)	(544.9M)	(517.7M)
Retained Earnings	1.5B	1.8B	2.5B	3.0B	3.5B	3.7B
Cash	439.1M	615.5M	762.6M	894.3M	853.9M	896.6M
Non Current Assets Total	1.3B	1.4B	1.6B	1.7B	1.9B	2.0B
Non Currrent Assets Other	20.5M	29M	36.3M	55.9M	38.4M	33.8M
Cash And Short Term Investments	439.1M	615.5M	762.6M	894.3M	853.9M	896.6M
Net Receivables	319.3M	385.3M	489M	507.4M	512M	537.6M
Liabilities And Stockholders Equity	2.3B	2.8B	3.3B	3.6B	3.8B	4.0B
Non Current Liabilities Total	426.6M	435.9M	384.3M	412.9M	276.7M	307.8M
Inventory	235.7M	321.3M	378.4M	414.8M	434.7M	456.4M
Other Current Assets	64.6M	51.6M	112M	103M	135.8M	142.6M
Other Stockholder Equity	154.6M	99.6M	19.5M	(138.7M)	(517.4M)	(491.5M)
Total Liab	768.2M	939.3M	978.4M	931.9M	948.5M	995.9M
Total Current Assets	1.1B	1.4B	1.7B	1.9B	1.9B	2.0B
Short Term Debt	11.9M	12.4M	53.5M	18.2M	151.7M	159.3M
Intangible Assets	29.8M	30.5M	23M	18.4M	15.1M	14.3M
Accounts Payable	156.8M	213.1M	232.2M	215.4M	242.4M	254.5M
Property Plant And Equipment Gross	909.4M	1.0B	2.2B	2.4B	2.8B	3.0B
Accumulated Other Comprehensive Income	(149.6M)	(110.6M)	(159.6M)	(183M)	(143.8M)	(151.0M)
Other Liab	109.2M	117M	112.5M	113.2M	130.2M	107.9M
Other Assets	43M	52.3M	104.4M	104M	93.6M	50.4M
Long Term Debt	255M	252.9M	208.8M	206.7M	72.8M	69.2M
Good Will	107.8M	111.1M	109.9M	107.3M	108.5M	103.1M
Treasury Stock	(118.1M)	(167.7M)	(229.5M)	(370.9M)	(333.8M)	(317.1M)
Property Plant Equipment	839.3M	943.2M	1.1B	1.2B	1.3B	1.4B
Current Deferred Revenue	27.5M	51M	48.7M	57.3M	41.7M	38.2M
Net Tangible Assets	1.4B	1.7B	2.1B	2.6B	2.9B	3.1B
Retained Earnings Total Equity	1.5B	1.8B	2.5B	3.0B	3.4B	3.6B
Long Term Debt Total	255M	252.9M	208.8M	206.7M	186.0M	209.4M
Capital Surpluse	272.7M	267.3M	249M	232.2M	267.0M	223.1M

West Pharmaceutical Investors Sentiment

The influence of West Pharmaceutical's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in West. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.

Investor biases related to West Pharmaceutical's public news can be used to forecast risks associated with an investment in West. The trend in average sentiment can be used to explain how an investor holding West can time the market purely based on public headlines and social activities around West Pharmaceutical Services. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.

West Pharmaceutical's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for West Pharmaceutical's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average West Pharmaceutical's news discussions. The higher the estimated score, the more favorable is the investor's outlook on West Pharmaceutical.

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards West Pharmaceutical in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, West Pharmaceutical's short interest history, or implied volatility extrapolated from West Pharmaceutical options trading.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

GM	General Motors
S	SentinelOne
MSFT	Microsoft

When determining whether West Pharmaceutical is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if West Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about West Pharmaceutical Services Stock. Highlighted below are key reports to facilitate an investment decision about West Pharmaceutical Services Stock:

How To Invest In West

Details

Is West Stock a good investment?

Details

What is West Pharmaceutical's Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in West Pharmaceutical Services. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.

You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.

Complementary Tools for West Stock analysis

When running West Pharmaceutical's price analysis, check to measure West Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy West Pharmaceutical is operating at the current time. Most of West Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of West Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move West Pharmaceutical's price. Additionally, you may evaluate how the addition of West Pharmaceutical to your portfolios can decrease your overall portfolio volatility.

	Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
	Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets
	Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
	Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
	Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm

Is West Pharmaceutical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of West Pharmaceutical. If investors know West will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about West Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.16)

Dividend Share

0.78

Earnings Share

7.57

Revenue Per Share

39.549

Quarterly Revenue Growth

(0.03)

The market value of West Pharmaceutical is measured differently than its book value, which is the value of West that is recorded on the company's balance sheet. Investors also form their own opinion of West Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is West Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because West Pharmaceutical's market value can be influenced by many factors that don't directly affect West Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between West Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if West Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, West Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

West Ebitda vs Cost Of Revenue Analysis

Ebitda vs Cost Of Revenue

Ebitda vs Cost Of Revenue Correlation Analysis

Correlation Coefficient

Ebitda

Cost Of Revenue

West Pharmaceutical fundamental ratios Correlations

West Pharmaceutical Account Relationship Matchups

High Positive Relationship

High Negative Relationship

West Pharmaceutical fundamental ratios Accounts

West Pharmaceutical Investors Sentiment

Also Currently Popular

Complementary Tools for West Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Common Stock	+ 1.0	Common Stock Total Equity
Inventory	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Total Assets
Retained Earnings	+ 0.99	Total Stockholder Equity
Net Receivables	+ 0.99	Total Stockholder Equity

Cash And Short Term Investments	- 0.95	Net Debt
Cash	- 0.95	Net Debt
Total Current Assets	- 0.93	Net Debt
Retained Earnings	- 0.93	Net Debt
Net Debt	- 0.93	Total Stockholder Equity
Net Receivables	- 0.92	Net Debt